ArticleBMC genomics2025
Universal amplification and sequencing of foot-and-mouth disease virus complete genomes using nanopore technology.
Article in BMC genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Evaluation of amplicon-based nanopore sequencing for foot-and-mouth disease viruses in clinical and environmental samples.Microbiology spectrum · 2026Article
- Spatial Patterns and Epidemiological Drivers of Foot-and-Mouth Disease Outbreaks in Uganda.Transboundary and emerging diseases · 2026Article
- MinION Adapted tNGS Panel for Carnivore Pathogens Including SARS-CoV-2.Pathogens (Basel, Switzerland) · 2025Article
- Nanopore sequencing in veterinary medicine: from concepts to clinical applications.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundFoot-and-mouth disease virus (FMDV) is capable of causing explosive outbreaks among domestic and wild cloven-hoofed animals. Genomic characterisation of FMDV is a crucial component of disease control enabling accurate tracing of disease outbreaks to be undertaken. Nanopore sequencing is an affordable and accessible form of high-throughput sequencing (HTS) technology. However, most published methods for FMDV only sequence genomic fragments or focus upon specific lineages. In this study, a universal FMDV sequencing protocol was developed alongside a bespoke analytical pipeline to sequence any FMDV genome in the absence of prior knowledge regarding the identity of the serotype or lineage.
methodsUniversal multiplex RT-PCRs were used to amplify overlapping tiles encompassing the entire FMDV genome. The PCR products were pooled and subjected to nanopore sequencing using the portable MinION sequencing device. A bioinformatics pipeline was used to assemble genomes based upon blastn and reference assembly.
resultsIterative changes in primer design and pooling resulted in two panels of primers; one set amplifying twenty short fragments (S_scheme), and another set amplifying six longer fragments (L_scheme). Both approaches were shown to be capable of generating FMDV genomes, however the L_scheme was simpler, more reliable and more cost-effective at generating complete genomes. The final L_scheme protocol was assessed using 30 FMDV isolates representing all the currently circulating lineages of FMDV. As part of the development, we successfully trialled the use of this technology in Uganda, a country endemic for FMD.
conclusionsThe amplification, sequencing and bioinformatics strategy developed here has been assessed using a diverse array of FMDV lineages. Using two multiplex PCR reactions, this approach can successfully generate complete genomes of FMDV in a lineage agnostic fashion. Therefore, the primer sets and approaches described here represent a useful tool for expanding the capacity of laboratories to characterise FMDV at the genomic level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.